New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
12:25 EDTARGS, ARGSArgos Therapeutics to host conference call
Conference call to discuss the data from Argos' completed Phase 2 combination study of AGS-003 in mRCC, presented at the recently held 2014 ASCO Annual Meeting will be held on June 9 at 1 pm. Webcast Link
News For ARGS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 3, 2015
10:26 EDTARGSArgos Therapeutics management to meet with FBR Capital
Subscribe for More Information
July 21, 2015
08:36 EDTARGSArgos Therapeutics announces formation of Scientific Advisory Board
Argos Therapeutics announced the formation of the company's first Scientific Advisory Board. Jeff Abbey, president and CEO of Argos, stated, "Forming a scientific advisory board is another important step as we continue to build Argos into a fully-integrated, commercial immuno-oncology company. These oncology and immunology experts will provide us with guidance on many clinical and technical aspects of our development programs. Their input is especially welcome as we continue our pivotal phase 3 ADAPT clinical trial of our lead product candidate, AGS-003, for the treatment of metastatic renal cell carcinoma, and as we plan to begin testing AGS-003 in other tumor types."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use